{"id":3712,"date":"2023-02-06T14:19:00","date_gmt":"2023-02-06T19:19:00","guid":{"rendered":"https:\/\/cpdc.ca\/psma-1007\/"},"modified":"2025-06-11T18:57:20","modified_gmt":"2025-06-11T22:57:20","slug":"psma-1007","status":"publish","type":"page","link":"https:\/\/cpdc.ca\/fr\/psma-1007\/","title":{"rendered":"PSMA-1007"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-page\" data-elementor-id=\"3712\" class=\"elementor elementor-3712 elementor-311\" data-elementor-post-type=\"page\">\n\t\t\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-80f81b8 elementor-section-boxed elementor-section-height-default elementor-section-height-default\" data-id=\"80f81b8\" data-element_type=\"section\" data-e-type=\"section\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-04adb44\" data-id=\"04adb44\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-2b49475 elementor-widget elementor-widget-heading\" data-id=\"2b49475\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">PSMA-1007<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-b26ac29 elementor-widget elementor-widget-heading\" data-id=\"b26ac29\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h2 class=\"elementor-heading-title elementor-size-default\">D\u00e9tecter. Diagnostiquer. D\u00e9cider.<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-fa4d86c elementor-widget elementor-widget-text-editor\" data-id=\"fa4d86c\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\tLe cancer de la prostate est la troisi\u00e8me cause de d\u00e9c\u00e8s par cancer chez les hommes canadiens. Afin d&rsquo;augmenter le nombre d&rsquo;agents diagnostiques sp\u00e9cifiques au cancer de la prostate au Canada, le CPDC a termin\u00e9 un <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT04644822?term=NCT04644822&amp;rank=1\">essai clinique de phase III <\/a>sur le [<sup>(18)<\/sup> F]PSMA-1007. Cet agent cible la prot\u00e9ine de l&rsquo;antig\u00e8ne membranaire sp\u00e9cifique de la prostate (PSMA) qui est surexprim\u00e9e dans le cancer de la prostate. Le PSMA-1007 devrait \u00eatre disponible pour les patients canadiens en 2026.\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<section class=\"elementor-section elementor-top-section elementor-element elementor-element-b88a1f2 elementor-section-content-middle animated-slow elementor-section-boxed elementor-section-height-default elementor-section-height-default elementor-invisible\" data-id=\"b88a1f2\" data-element_type=\"section\" data-e-type=\"section\" data-settings=\"{&quot;animation&quot;:&quot;fadeIn&quot;}\">\n\t\t\t\t\t\t<div class=\"elementor-container elementor-column-gap-default\">\n\t\t\t\t\t<div class=\"elementor-column elementor-col-66 elementor-top-column elementor-element elementor-element-10ebc86\" data-id=\"10ebc86\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-aa31043 elementor-widget elementor-widget-image\" data-id=\"aa31043\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"image.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<img fetchpriority=\"high\" decoding=\"async\" width=\"624\" height=\"271\" src=\"https:\/\/cpdc.ca\/wp-content\/uploads\/2025\/06\/psma3.png\" class=\"attachment-full size-full wp-image-4247\" alt=\"\" srcset=\"https:\/\/cpdc.ca\/wp-content\/uploads\/2025\/06\/psma3.png 624w, https:\/\/cpdc.ca\/wp-content\/uploads\/2025\/06\/psma3-300x130.png 300w\" sizes=\"(max-width: 624px) 100vw, 624px\" \/>\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-0fc22f6 elementor-widget elementor-widget-text-editor\" data-id=\"0fc22f6\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>Image adapt\u00e9e de Giesel, F.L., Hadaschik, B., Cardinale, J. <em>et al.<\/em> PSMA-1007 marqu\u00e9 au F-18 : biodistribution, dosim\u00e9trie des rayonnements et validation histopathologique des l\u00e9sions tumorales chez des patients atteints d&rsquo;un cancer de la prostate. <em>Eur J Nucl Med Mol Imaging<\/em> <strong>44<\/strong>, 678\u2013688 (2017). https:\/\/doi.org\/10.1007\/s00259-016-3573-4. L&rsquo;image n&rsquo;a subi aucune modification. Cliquez <a href=\"https:\/\/s100.copyright.com\/AppDispatchServlet?title=The%20value%20of%2018F-PSMA-1007%20PET%2FCT%20in%20identifying%20non-metastatic%20high-risk%20prostate%20cancer&amp;author=Jun-jie%20Hong%20et%20al&amp;contentID=10.1186%2Fs13550-020-00730-1&amp;copyright=The%20Author%28s%29&amp;publication=2191-219X&amp;publicationDate=2020-11-10&amp;publisherName=SpringerNature&amp;orderBeanReset=true&amp;oa=CC%20BY\">ici<\/a> pour obtenir la licence Creative Commons permettant sa publication.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t<div class=\"elementor-column elementor-col-33 elementor-top-column elementor-element elementor-element-7074dff\" data-id=\"7074dff\" data-element_type=\"column\" data-e-type=\"column\">\n\t\t\t<div class=\"elementor-widget-wrap elementor-element-populated\">\n\t\t\t\t\t\t<div class=\"elementor-element elementor-element-436e575 elementor-widget elementor-widget-text-editor\" data-id=\"436e575\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>CPDC d\u00e9tient les droits de licence exclusifs pour le PSMA-1007 d&rsquo;ABX GmbH (Radeberg, Allemagne) pour fabriquer, commercialiser et distribuer l&rsquo;agent d&rsquo;imagerie au Canada. CPDC s&rsquo;efforce de mettre sur le march\u00e9 canadien un outil de diagnostic du cancer de la prostate d&rsquo;une importance cruciale.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>PSMA-1007 D\u00e9tecter. Diagnostiquer. D\u00e9cider. Le cancer de la prostate est la troisi\u00e8me cause de d\u00e9c\u00e8s par cancer chez les hommes canadiens. Afin d&rsquo;augmenter le nombre d&rsquo;agents diagnostiques sp\u00e9cifiques au cancer de la prostate au Canada, le CPDC a termin\u00e9 un essai clinique de phase III sur le [(18) F]PSMA-1007. Cet agent cible la prot\u00e9ine de &#8230; <a title=\"PSMA-1007\" class=\"read-more\" href=\"https:\/\/cpdc.ca\/fr\/psma-1007\/\" aria-label=\"Read more about PSMA-1007\">Read more<\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"elementor_header_footer","meta":{"footnotes":""},"class_list":["post-3712","page","type-page","status-publish"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/cpdc.ca\/fr\/wp-json\/wp\/v2\/pages\/3712","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/cpdc.ca\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/cpdc.ca\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/cpdc.ca\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/cpdc.ca\/fr\/wp-json\/wp\/v2\/comments?post=3712"}],"version-history":[{"count":33,"href":"https:\/\/cpdc.ca\/fr\/wp-json\/wp\/v2\/pages\/3712\/revisions"}],"predecessor-version":[{"id":4264,"href":"https:\/\/cpdc.ca\/fr\/wp-json\/wp\/v2\/pages\/3712\/revisions\/4264"}],"wp:attachment":[{"href":"https:\/\/cpdc.ca\/fr\/wp-json\/wp\/v2\/media?parent=3712"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}